MacuCLEAR, Mystic completes Phase Ib study enrollment

MC-1101, a new compound under investigation for the treatment and prevention of the progression of age-related macular degeneration (AMD), developers MacuCLEAR (Plano, Texas) and Mystic Pharmaceuticals said in a news release. The preliminary results indicated that MacuCLEAR’s MC-1101 drug is safe and well tolerated by study participants, and has a biological effect on blood flow in the back of the retina. Trial participants used the VersiDoser ophthalmic delivery system (Mystic) to self-administer MC-1101 to the front of the eye during the trial, the companies said. Full results are expected later this year.

If you enjoyed this post, make sure you subscribe to my RSS feed!